Hainan Periwinkle Pharmaceutical Co., Ltd. was established in 2005 with registered capital of 50 million RMB. Located in the Meian Industrial Park of the National High-Tech Industrial Development Zone in Haikou, Hainan Province, China, it is a research-driven pharmaceutical enterprise integrating drug research, manufacturing, and sales. The company specializes in the research and production of Periwinkle series anti-cancer drugs, with multiple GMP production lines for high-activity raw materials, injection liquid, lyophilized powder injection, and soft capsules. It also have complete and advanced production and inspection equipment.

The company is focused on technological innovation and project research, and has achieved rapid development in recent years: it passed the "High-Tech Enterprise" certification in 2020, became a "Specialized, and Innovative" small and medium-sized enterprise in Hainan Province in 2021, and was recognized as a "Hainan High-Tech Gazelle Enterprise" in the Hainan High-Tech Enterprise "Elite Action" in 2022. The company has obtained a dozen of China patents for invention and several utility model patents, and has been recognized as a national enterprise with intellectual property advantages.

       The core product line of the company is the Periwinkle series anti-cancer drugs, including raw materials (vincristine sulfate, vinblastine sulfate, vindesine sulfate, and vinorelbine tartrate) and formulations (injection of vincristine sulfate, vincristine sulfate injection, and vinorelbine tartrate soft capsules, etc.), whose quality meets the standards of the ChP/USP/EP/JP, and is at the international leading level. Our Periwinkle products have been exported to professional anti-cancer drug manufacturers in Europe, Mexico, Chile, South Africa, and India, and have received consistent praise.

       The company is actively laying out the research and development of new products, cultivation, tourism, high-end formulations, and other upstream and downstream industrial chains. Hainan Periwinkle Pharmaceutical Co., Ltd. has always adhered to its unremitting pursuit of drug quality and safety, and strives to benefit the vast number of patients with high-quality products. It uses practical actions to fulfill its mission of "passing on healthy positive energy" and is committed to becoming the world's No. 1 in the field of Periwinkle series anti-cancer drugs.